Navigating the Advancements in Oral Therapy Options in HR+ Metastatic Breast Cancer

This activity was originally broadcast in conjunction with AMCP 2025.

Program Description

The managed care environment faces new pharmacoeconomic barriers with the increasing complexity of targeted therapies and introduction of novel agents in the treatment of HR+/HER2– metastatic breast cancer. Mutational testing is paramount to guide the appropriate selection of therapies in both the frontline setting and for disease progression. From a managed care perspective, the rising cost of managing metastatic breast cancer requires careful consideration of resource utilization. Experts will lead a discussion on strategies for managed care professionals to improve access to oral treatments for HR+/HER2– metastatic breast cancer, appropriately apply genomic testing to ensure biomarker-directed therapy, and facilitate coverage policies that support patient access to care.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 10, 2025
Expiration date: April 10, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply the guideline recommendations for mutational testing and associated treatment selection in HR+ metastatic breast cancer.
• Compare recent clinical trial data for triplet regimen with the historic standard of care in frontline treatment algorithms for HR+/HER2– metastatic breast cancer.
• Analyze the evolving role of oral targeted agents and selective estrogen receptor degraders in the management of HR+/HER2– metastatic breast cancer.
• Investigate the impact of recent clinical updates on formulary decisions, treatment pathways, and resource allocation for patients with HR+/HER2– metastatic breast cancer within operational and managed care frameworks.